General Information of the Drug (ID: M6APDG03562)
Name
ISIS 116507
Status
Investigative
TTD Drug ID
D0TD0K
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
C/EBP beta messenger RNA (CEBPB mRNA)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
Response Summary C/EBP beta messenger RNA (CEBPB mRNA) is a therapeutic target for ISIS 116507. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 116507 through regulating the expression of C/EBP beta messenger RNA (CEBPB mRNA). [1], [2]
References
Ref 1 METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m(6)A Modification. Cell Stem Cell. 2018 Feb 1;22(2):191-205.e9. doi: 10.1016/j.stem.2017.11.016. Epub 2017 Dec 28.
Ref 2 US patent application no. 6,271,030, Antisense inhibition of C/EBP beta expression.